Systematic review followed by an individual patient data meta-analysis concluded that all non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, were found to be associated with an increased risk of acute myocardial infarction (AMI). Risk of AMI with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib. Risk was greatest during the first month of NSAID use and with higher doses. A cohort of 446 763 individuals including 61 460 with AMI was acquired. Taking any dose of NSAIDs for one week, one month, or more than a month was associated with an increased risk of AMI. With use for one to seven days the probability of increased AMI risk (posterior probability of odds ratio >1.0) was 92% for celecoxib, 97% for ibuprofen, and 99% for diclofenac, naproxen, and rofecoxib. The corresponding odds ratios were 1.24 for celecoxib, 1.48 for ibuprofen, 1.50 for diclofenac, 1.53 for naproxen, and 1.58 for rofecoxib. Greater risk of AMI was documented for higher dose of NSAIDs. With use for longer than one month, risks did not appear to exceed those associated with shorter durations. Source: http://www.bmj.com/
Long-term follow-up of two randomized lifestyle intervention trials found that reducing visceral fat—not simply losing…
Recently identified brain rhythm during sleep may play a crucial role in clearing neurotoxic waste…
A US community-based study found that middle-aged adults with blood biomarkers indicating Alzheimer’s disease neuropathology…
A randomized clinical trial found that a single 25 mg dose of psilocybin produced rapid…
The American Cancer Society (ACS) reaffirmed that average-risk adults should begin colorectal cancer (CRC) screening…
A comprehensive systematic review and meta-analysis involving 69 randomized controlled trials and 153,902 adults found…
This website uses cookies.